Lublin and Reingold described terms for the different time courses shown by patients with multiple sclerosis. These can help identify patients who may benefit from more aggressive management. The authors are from the Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis for the National Multiple Sclerosis Society.